Bionano Genomics shares fall 13.70% intraday after Q4 revenue declines 3% to $8 million.

Bionano Genomics (NASDAQ:BNGO) fell 13.70% intraday following the release of its Q4 2025 earnings report, which highlighted a 3% year-over-year revenue decline to $8 million and a 7% full-year revenue drop to $28.5 million. The report also revealed a 6% decline in flow cell sales for Q4 and supply chain constraints affecting consumables. While the company cited improved non-GAAP gross margins (43% in Q4, 47% full year) and a 47% year-over-year reduction in operating expenses, the revenue underperformance and operational challenges overshadowed these positives. The stock’s intraday selloff reflects investor concern over persistent revenue declines and supply-side headwinds, despite the company exceeding OGM system installation guidance and maintaining a strong cash position.